More than 7,000 natural polypeptides have been identified, playing roles in human physiology such as hormones and neurotransmitters. Therapeutic polypeptides are seeing renewed commercial interest after wide use in pharmaceuticals over the past decade. Advances in multifunctional peptides like…
Researchers have identified more than 7,000 kinds of naturally occurring polypeptides. These molecules serve critical functions in human physiology. They act as hormones, neurotransmitters, growth factors, ion channel ligands, and agents with anti-inflammatory effects.
Over the past decade, polypeptides have found broad use in pharmaceutical and biotechnology sectors. Therapeutic polypeptides are experiencing a commercial revival. This trend highlights their growing importance in medicine.
Multifunctional peptides, particularly GLP-1 agonists, have seen significant progress in metabolic disorders. In areas like the gut, microbes offer diverse bacteria that recognize protein fragments, degradation products, and peptides from signaling molecules. Deeper microbiological research will create many chances for peptide-based treatments.
Certain natural polypeptides stand out for their strong therapeutic effects. Tumor Antigen-derived Peptides represent one such example. These developments point to rich potential in peptide therapeutics.
To advance new peptide drugs, chemists need to move beyond standard peptide methods. Multifunctional peptides that deliver multiple pharmacological actions, like double or triple agonism, mark a key emerging approach. This relies on genomic data requirements.
Knockout animals typically target only a single gene, often lacking a distinct phenotype. For G protein coupled receptors, several selective agonists and antagonists have entered clinical stages, but few ligands gain approval. Drug efforts supply useful biological models and multi-target strategies, while also enabling poly-pharmacology for tailored patient care.
Current multifunctional peptide candidates, such as antimicrobial types, often include extra functions like immune stimulation and wound healing. In the GLP-1 agonist area, products like Byetta, Bydureon, Victoza, Lyxumia, Tanzeum, and DOTA-cyclo RGDfK acetate have received approval and strong market success.
Efforts focus on better patient adherence through less frequent dosing or oral GLP-1 options now in clinical trials. Recent technologies improve membrane permeability with cell-penetrating peptides. Examples include the trans-activator of transcription TAT sequence, which helps reach intracellular targets but risks reduced potency.
Developers must assess if these peptides mimic small molecules in traits like low specificity. Larger distribution volumes can raise safety concerns. Polypeptides also form conjugates with small molecules, oligoribonucleotides, and antibodies to boost efficacy and safety.
In oncology, this conjugate approach has drawn industry attention, with more than 20 polypeptide conjugates in clinical trials. Future polypeptide drug progress will build on native peptide strengths. It will pair these with classic design principles to address limits in chemical and physical properties.
Technologies like multifunctional peptides, cell-penetrating peptides, and peptide conjugates will broaden modern therapeutic peptide uses. All these elements support the view that peptides hold great promise for future medical treatments.
Peptides referenced: Liraglutide, Exenatide, Lixisenatide, Albiglutide, GLP-1.
Related reading: Figure 2: Antimicrobial Peptide Axes Governing Amyloid Cross-Seeding, Penn Study: Inconsistent GLP-1 Use May Cause Weight Gain, Cell-Penetrating Peptides Aid Intracellular Delivery, GnRH3 Neuropeptide Regulates PGC Proliferation and Sex Differentiation in Zebrafish.